Last reviewed · How we verify

NCT06936163: HSP

A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSP

Recruiting now Last updated 20 April 2025
What this trial tests

trial in Hereditary Spastic Paraplegia in 100 participants. Currently enrolling.

Timeline
1 March 2025
Primary endpoint
31 March 2027
30 April 2027

Quick facts

Lead sponsorShanghai 6th People's Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date1 March 2025
Primary completion31 March 2027
Estimated completion30 April 2027
Sites1 location across China

Conditions studied

Sponsor

Shanghai 6th People's Hospital

Who can join

Adults 10 to 45, any sex, with Hereditary Spastic Paraplegia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through a prospective cohort study, we aim to dynamically evaluate the long-term benefits and risks associated with surgical interventions for hereditary spastic paraparesis (HSP) accompanied by foot deformities. Our goal is to systematically summarize clinical experiences to guide practice and ultimately optimize patient outcomes. The core research objectives include elucidating: 1. the long-term efficacy of foot deformity correction procedures; 2. the optimal timing for surgical intervention; 3. the establishment of objective evaluation criteria to guide therapeutic decision-making.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hereditary Spastic Paraplegia

Currently open trials in the same condition.

Other Shanghai 6th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06936163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing